The global minimal residual disease testing market is poised to reach $2.3 billion by 2027, growing at a CAGR of 14.0% from 2022 to 2027.
According to research report the global minimal residual disease testing market is projected to reach $2.3 billion by 2027, growing at a CAGR of 14.0% from 2022. Key factors driving this market expansion include the rising prevalence of cancer and hematological malignancies, increasing government initiatives to raise awareness about cancer, and growing collaborations among stakeholders. Emerging economies like China, Japan, and India present lucrative opportunities for market players.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215386038
Driver: Rising incidence of hematological malignancies
Over the years, the incidence of hematologic cancer has increased significantly, which includes leukemia and lymphoma. According to the Leukemia & Lymphoma Society 2020-2021, an estimated 1,519,907 people in the US are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). Also, the rising geriatric population across the globe is also a key factor supporting the increasing incidence of hematologic malignancies, as this population segment is more prone to various chronic diseases. Such cancer patients require continuous monitoring of disease during treatment. Also, the monitoring of minimal residual diseases (MRD) has become a routine clinical practice post-cancer treatment. As a result, the preference for minimal residual disease testing will likely rise in the forecast period, proportional to the growth in cancer prevalence.
Segmentation Insights:
By Technology:
– The polymerase chain reaction (PCR) segment held the largest share in 2021 due to its ease of use, availability, relative sensitivity, and cost-efficiency.
By Application:
– The hematological malignancies segment is expected to register the highest growth rate during the forecast period, primarily driven by the increasing incidence of leukemia and lymphoma, necessitating continuous patient monitoring.
By End-User:
– In 2021, the hospitals and specialty clinics segment accounted for the largest share owing to the availability of advanced diagnostic devices and skilled healthcare professionals.
Regional Analysis:
– North America dominated the MRD testing market, attributed to the growing incidence of hematological malignancies, well-developed healthcare systems, the presence of leading clinical laboratories, and easy access to advanced diagnostic instruments.
Key Players:
Labcorp Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Sysmex Corporation, NeoGenomics Laboratories, Inc., Adaptive Biotechnologies Corporation, ArcherDX, Inc., Asuragen Inc., Arup Laboratories Inc., Bio-Rad Laboratories, Inc., Cergentis B.V., Molecular MD (ICON plc), Invivoscribe, Inc., Mission Bio, Inc., Natera, Inc., Opko Health, Inc., Quest Diagnostics, and Genetron Health, among others.
Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215386038
The report provides a comprehensive analysis of the MRD testing market, including market size, growth projections, segmentation insights, regional dynamics, and competitive landscape. It offers valuable insights for companies operating in this space and those seeking to enter or expand their presence in the MRD testing market.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
© 2024 Crivva - Business Promotion. All rights reserved.